celecoxib has been researched along with hydroxyurea in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Achucarro, P; Guski, H; Heinicken, D; Jacobi, CA; Kilian, M; Müller, JM; Schimke, I; Wenger, FA | 1 |
| Bisevac, M; Guski, H; Khodadayan, C; Kilian, M; Müller, JM; Schimke, I; von Seebach, M; Wenger, FA | 1 |
| Chacur, M; Cury, Y; Guerra, JL; Gutiérrez, JM; Lomonte, B; Longo, I; Picolo, G; Teixeira, CF | 1 |
| Fiorucci, S; Hollenberg, MD; von der Weid, PY; Wallace, JL | 1 |
| Beer, DG; Chen, X; Giordano, TJ; Jin, Z; Lin, Y; Lubet, RA; Shih, WC; Sood, S; Wang, P; Wang, S; Wu, N; Yang, CS | 1 |
| Chen, X; Fang, M; Li, N; Sood, S; Sun, Z; Wang, P; Wang, S; Yang, CS | 1 |
| Gregor, JI; Heukamp, I; Jacobi, CA; Kiewert, C; Kilian, M; Kristiansen, G; Schimke, I; Walz, MK; Wenger, FA | 1 |
| Liu, DS; Zhang, GS | 1 |
| Hénichart, JP; Pommery, J; Pommery, N | 1 |
| Dai, CW; Li, RJ; Liu, DS; Zhang, GS | 1 |
| Amann, JM; Backlund, MG; Johnson, DH | 1 |
| Bedor, M; Edelman, MJ; Gajra, A; Green, MJ; Hodgson, L; Jewell, S; Kratzke, RA; Masters, GA; Mauer, AM; Morrison, C; Vokes, EE; Wang, X; Watson, D | 1 |
| Anderson, GD; De Ciechi, PA; Keys, KL; Masferrer, JL | 1 |
| Fegn, L; Wang, Z | 1 |
| Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Phillips, JM; Steele, VE | 1 |
| Akpa, EG; Bosworth, BP; Boyle, JO; Brown, PH; Dannenberg, AJ; Duffield-Lillico, AJ; Kingsley, PJ; Knutson, A; Marnett, LJ; Milne, GL; Mohebati, A; Szabo, E; Zhou, XK | 1 |
| Altavilla, D; Arcoraci, V; Bitto, A; Galfo, F; Irrera, N; Macrì, A; Minutoli, L; Pallio, G; Pizzino, G; Squadrito, F; Squadrito, G | 1 |
1 review(s) available for celecoxib and hydroxyurea
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for celecoxib and hydroxyurea
| Article | Year |
|---|---|
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Eicosanoids; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Up-Regulation | 2008 |
Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Topics: Adult; Arachidonate 5-Lipoxygenase; Biomarkers; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Hydroxyurea; Leukotriene E4; Lipoxygenase Inhibitors; Male; Maximum Tolerated Dose; Prognosis; Prostaglandins; Pyrazoles; Smoking; Sulfonamides; Tandem Mass Spectrometry | 2013 |
18 other study(ies) available for celecoxib and hydroxyurea
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Celecoxib; Cricetinae; Glutathione; Hydroxyurea; Incidence; Lipoxygenase Inhibitors; Male; Mesocricetus; Pancreas; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2002 |
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cricetinae; Hydroxyurea; Lipid Peroxidation; Lipoxygenase Inhibitors; Liver Neoplasms; Male; Mesocricetus; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2002 |
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants.
Topics: Animals; Bothrops; Bradykinin; Carrageenan; Celecoxib; Crotalid Venoms; Heparin; Hindlimb; Histamine Antagonists; Hydroxyurea; Hyperalgesia; Male; omega-N-Methylarginine; Peptides; Phospholipases A; Pyrazoles; Rats; Rats, Wistar; Serotonin Antagonists; Sulfonamides; Time Factors | 2003 |
Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone.
Topics: Acetylcholine; Animals; Aorta; Aspirin; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelium, Vascular; Hydroxyurea; Lipoxins; Lipoxygenase Inhibitors; Male; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroarginine; Oligopeptides; Pyrazoles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Lipoxin; Sulfonamides; Vascular Resistance; Vasodilation; Vasodilator Agents | 2004 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Body Weight; Celecoxib; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal Neoplasms; Humans; Hydroxyurea; Immunohistochemistry; Leukotriene B4; Lipoxygenase Inhibitors; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2004 |
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carcinogens; Carcinoma, Squamous Cell; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Cricetinae; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Humans; Hydroxyurea; Immunohistochemistry; In Situ Hybridization; Lipoxygenase Inhibitors; Male; Membrane Proteins; Mesocricetus; Mouth Neoplasms; Neoplasms, Experimental; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Up-Regulation | 2005 |
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cricetinae; Cyclooxygenase Inhibitors; Dinoprostone; Drug Therapy, Combination; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Liver; Liver Neoplasms; Pancreas; Pancreatic Neoplasms; Prostaglandins; Prostaglandins F; Pyrazoles; Sulfonamides | 2005 |
[Effect of celecoxib on enhancing the chemotherapic sensitivity of hydroxyurea to K562 cells and its mechanism].
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Humans; Hydroxyurea; K562 Cells; Pyrazoles; RNA, Messenger; Sulfonamides | 2004 |
Modification of eicosanoid profile in human blood treated by dual COX/LOX inhibitors.
Topics: Arachidonic Acid; Calcimycin; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Eicosanoids; Humans; Hydroxyurea; Indomethacin; Inhibitory Concentration 50; Lipopolysaccharides; Lipoxygenase Inhibitors; Pyrazoles; Sulfonamides | 2005 |
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Marrow Cells; Caspase 3; Caspase Inhibitors; Caspases; Celecoxib; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; G1 Phase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Hydroxyurea; Imatinib Mesylate; Interleukin-1; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Pyrazoles; Pyrimidines; S Phase; Sulfonamides | 2006 |
Novel strategies for the treatment of lung cancer: modulation of eicosanoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Eicosanoids; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Lung Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Up-Regulation | 2008 |
Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Epoxide Hydrolases; Humans; Hydroxyurea; Leukotriene B4; Leukotrienes; Male; Mice; Mice, Inbred DBA; Prostaglandins; Pyrazoles; RNA, Messenger; Sulfonamides | 2009 |
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Combinations; Head and Neck Neoplasms; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Mice, Nude; Pyrazoles; Random Allocation; Skin Neoplasms; Sulfonamides | 2009 |
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Gene Expression; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mouth Neoplasms; Naproxen; Piroxicam; Pyrazoles; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Up-Regulation | 2010 |
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Body Weight; Catechin; CD3 Complex; Celecoxib; Colitis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Combinations; Eating; Gene Expression Regulation; Hydroxyurea; Leukotriene B4; Lipid Peroxidation; Lipoxygenase Inhibitors; Male; Neutrophil Infiltration; Rats; Rats, Sprague-Dawley; Thromboxane B2; Tumor Necrosis Factor-alpha | 2016 |